Pembrolizumab companion diagnostic - Merck/NanoString Technologies
Latest Information Update: 03 Jul 2015
At a glance
- Originator NanoString Technologies
- Developer Merck & Co; NanoString Technologies
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Clinical Phase Unknown Cancer
Most Recent Events
- 28 May 2015 Clinical trials in Cancer (Diagnosis) in World (unspecified route)